PDCD1 and neoplasm: This combination builds on the concept that the CXCR4 blockade may increase immune infiltration in the tumour microenvironment via reduction in T regulatory cells and myeloid-derived suppressor (MDSC) cells, thus promoting the activity of PD-1 inhibitors [132].